Using CancerenD24 to help diagnose cancer early
Clinical Validation Of A Diagnostic Cancerend24 Screening As An Aid To The Clinician For The Diagnosis Of Cancer In Healthy Subjects Attending The ICPC
This study is testing a new blood test called CancerenD24 to see if it can help find cancer early in people aged 40 and older, even before they have any symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT06656728 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the CancerenD24 index, which utilizes an algorithm based on the expression levels of CD24 and CD11b proteins in blood samples to assist in the early detection of cancer. The study will recruit 2000 participants aged 40 and older, who will undergo routine blood tests to measure these protein levels alongside clinical and laboratory characteristics. The goal is to determine if this method can effectively identify malignant diseases in healthy individuals before symptoms arise. The test is designed for routine clinical use and is not influenced by fasting or the time of day when samples are collected.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy individuals aged 40 and older who are willing to participate and provide informed consent.
Not a fit: Patients under 40 years of age, those with active cancer, or individuals with certain medical conditions such as inflammatory bowel disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance early cancer detection, leading to better treatment outcomes for patients.
How similar studies have performed: Other studies have explored similar blood-based biomarkers for cancer detection, showing promising results, but the CancerenD24 approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information 2. Willing and able to sign an informed consent 3. Age ≥40 years Exclusion Criteria: 1. Age \< 40 years 2. Pregnancy or breastfeeding 3. Any type of fever 4. Any cancer active at study entry or up to 5 years prior to study entry 5. Polyposis syndromes 6. Inflammatory bowel disease 7. Unwilling or unable to provide informed consent
Where this trial is running
Tel Aviv
- Integrated Cancer Prevention Center at the Tel Aviv Sourasky Medical Center Ichilov — Tel Aviv, Israel (Recruiting)
Study contacts
- Study coordinator: Nadir Arber, Professor
- Email: nadira@tlvmc.gov.il
- Phone: +972 036973561
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.